NCT07559877 Topical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma:
| NCT ID | NCT07559877 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Jiangxi Provincial Cancer Hospital |
| Condition | Nasopharangeal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 148 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 148 participants in total. It began in 2026-04-01 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigated the effects of topical chlorhexidine spray on the incidence, severity, and quality of life during radiotherapy in nasopharyngeal carcinoma patients.
Eligibility Criteria
Inclusion Criteria: Histologically or cytologically confirmed nasopharyngeal carcinoma. Clinical stage II-III disease with N≥1, according to the UICC/AJCC 9th edition. Planned to receive first-course definitive chemoradiotherapy, with a total radiotherapy dose of 60-70 Gy. Able to communicate and complete study assessments. Willing to participate and able to provide written informed consent. Eligible based on baseline assessments performed before chemoradiotherapy. Exclusion Criteria: * History of or current psychiatric disorder, cognitive impairment, or other severe organic disease. Presence of another concomitant malignancy. Receipt of any other prophylactic intervention for radiation dermatitis. Pre-existing skin disease before chemoradiotherapy. Known hypersensitivity or allergy to chlorhexidine.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07559877 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Nasopharangeal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07559877 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 148 participants.
Is NCT07559877 currently recruiting?
Yes, NCT07559877 is actively recruiting participants. Contact the research team at lutianzhu2008@163.com for enrollment information.
Where is the NCT07559877 trial being conducted?
This trial is being conducted at Nanchang, China.
Who is sponsoring the NCT07559877 clinical trial?
NCT07559877 is sponsored by Jiangxi Provincial Cancer Hospital. The trial plans to enroll 148 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.